{"hq_id":"hq-p-spe-000195","name":"Heated Tobacco Product IQOS (Heat-Not-Burn, Reduced but Not Eliminated Toxicant Exposure, Formaldehyde and Acrolein)","category":{"primary":"nicotine","secondary":"heated_tobacco","tags":["IQOS","heated tobacco","heat-not-burn","HnB","Philip Morris","formaldehyde","acrolein","reduced risk","modified risk","MRTP"]},"product_tier":"SPE","overall_risk_level":"moderate","description":"IQOS (I Quit Original Smoking), manufactured by Philip Morris International, is a heated tobacco product (HTP) that heats specially designed tobacco sticks (HEETS/Terea) to approximately 350C using an electronically controlled blade or induction system, producing a nicotine-containing aerosol without combustion. Because the tobacco is heated rather than burned (combustion occurs above 600C), IQOS aerosol contains 80-95% lower levels of many harmful and potentially harmful constituents (HPHCs) compared to cigarette smoke, including carbon monoxide, acrolein, formaldehyde, benzene, and tobacco-specific nitrosamines. However, 'reduced' does not mean 'eliminated' — formaldehyde, acrolein, acetaldehyde, and glycidol are still present in IQOS aerosol at toxicologically relevant concentrations. The FDA authorized IQOS as a Modified Risk Tobacco Product (MRTP) in 2020 with the limited claim that it 'reduces exposure' to certain chemicals (not that it reduces disease risk), making it the first tobacco product to receive this designation. Philip Morris's own data shows IQOS delivers 70-80% of the nicotine of a combustible cigarette, maintaining addiction potential. Independent studies have found that IQOS heats above its nominal temperature range, potentially approaching pyrolysis conditions at the blade surface.","synthesis":{"derived_risk_level":"moderate_to_high","synthesis_confidence":0.628,"synthesis_method":"compound_composition","context_used":"human_adult","context_source":"product_users","exposure_modifier":1.15,"vulnerability_escalated":false,"escalation_reason":null,"compounds_resolved":2,"compounds_total":2,"synthesis_date":"2026-05-09","synthesis_version":"1.2.0","methodology_note":"exposure_modifier and adjusted_magnitude are computed from ALETHEIA-calibrated heuristics (route × duration × frequency multipliers, clamped to [0.5, 1.4]). Multipliers are directionally informed by EPA Exposure Factors Handbook (2011) and CalEPA OEHHA but are not regulatory consensus. See /api/methodology for full disclosure."},"hazard_summary":{"sensitive_populations":"non-smokers who may initiate use based on reduced-risk perception, pregnant women (nicotine causes fetal harm regardless of delivery system), adolescents, individuals with cardiovascular disease","overall_risk":"moderate","primary_concerns":["Reduced toxicant exposure (80-95% lower) does NOT mean reduced disease risk — FDA explicitly did not authorize that claim","Nicotine delivery at 70-80% of cigarette level maintains full addiction potential","Formaldehyde, acrolein, and glycidol still present at toxicologically relevant levels","Dual use (IQOS + cigarettes) — most common real-world pattern — provides minimal toxicant reduction"],"exposure_routes":"Inhalation (sole route — heated tobacco aerosol containing reduced but non-zero levels of formaldehyde, acrolein, CO, TSNAs, and other HPHCs)."},"exposure":{"routes":["inhalation"],"contact_types":["inhalation_aerosol"],"users":["adult"],"duration":"chronic","frequency":"daily","scenarios":["Current smoker switches to IQOS — reduced but not eliminated exposure to formaldehyde, acrolein, CO, and TSNAs","Dual user alternates between IQOS and cigarettes — no meaningful toxicant reduction from partial switching","Non-smoker initiates IQOS use based on 'reduced risk' marketing — acquires nicotine addiction with non-zero toxicant exposure","Blade overheating at end of stick produces localized pyrolysis conditions exceeding nominal 350C heating range"],"notes":"IQOS: electrically heated blade or induction system heats HEETS/Terea tobacco sticks to ~350C (vs cigarette combustion >600C). PMI data: 80-95% reduction in 58 HPHCs (FDA MRTP review). Independent analysis: formaldehyde 2-14 ug/stick (vs 50-100 ug cigarette), acrolein 1-5 ug/stick (vs 60-100 ug), CO 0.3-0.5 mg/stick (vs 10-25 mg). FDA MRTP authorization (July 2020): exposure modification order only — specifically does NOT authorize claims of reduced disease risk. Dual use concern: 60-80% of IQOS users in Japan continue some cigarette use (cross-sectional data). Glycidol (IARC 2A carcinogen) uniquely elevated in IQOS aerosol relative to cigarettes (Salman et al., Chem Res Toxicol 2019)."},"consumer_guidance":{"usage_warning":"IQOS reduces exposure to many harmful chemicals compared to cigarette smoke, but is NOT risk-free. The FDA specifically authorized the claim that IQOS 'reduces exposure' — NOT that it reduces disease risk. Do not use if you are a non-smoker or former smoker — IQOS delivers nicotine at levels that maintain addiction. Complete smoking cessation (not product switching) remains the gold standard for health benefit. If using IQOS, do not dual-use with cigarettes — this eliminates most of the exposure reduction benefit. Follow manufacturer instructions for device cleaning to prevent residue buildup that increases toxicant generation.","safer_alternatives":["Complete smoking and nicotine cessation (greatest health benefit)","FDA-approved nicotine replacement therapy (patch, gum, lozenge)","Prescription cessation medications (varenicline, bupropion)","If continuing to use nicotine: pharmaceutical-grade nicotine products over any tobacco-derived aerosol"]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA Modified Risk Tobacco Product (MRTP) Authorization for IQOS","citation":"FDA MRTP Order PM0000424-PM0000427 (July 7, 2020); FD&C Act Section 911","requirements":"FDA authorized IQOS as the first MRTP with an 'exposure modification' order permitting the claim: 'Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body's exposure to harmful or potentially harmful chemicals.' Order explicitly does NOT authorize disease risk reduction claims. Requires post-market surveillance, annual reports, and restrictions on marketing to youth. IQOS may only be sold to adults.","compliance_status":null,"effective_date":"2020-07-07","enforcing_agency":"FDA Center for Tobacco Products","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"IQOS device contains lithium battery — dispose as electronic waste. Used HEETS/Terea sticks contain tobacco residue and should be disposed in regular trash (not littered).","hazardous_waste":false,"expected_lifespan":"IQOS device: 1-2 years with regular cleaning. HEETS/Terea sticks: single use."},"formulation":{"form":"varies","key_ingredients":[],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-000080","compound_name":null,"role":"active_constituent","typical_concentration":"nicotine delivery approximately 70-80% of combustible cigarette; maintains full addiction potential via tobacco-derived nicotine"},{"hq_id":"hq-c-org-000011","compound_name":null,"role":"thermal_decomposition_product","typical_concentration":"formaldehyde in IQOS aerosol reduced 80-95% vs cigarette smoke but still detected at 2-14 ug per stick (vs 50-100 ug cigarette)"}],"identifiers":{"common_names":["heated tobacco product iqos (heat-not-burn, reduced but not eliminated toxicant exposure, formaldehyde and acrolein)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[],"brand_examples_disclaimer":null,"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-26"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-26","timestamp":"2026-05-14T01:29:31.390Z"}}